ACTUATE THERAPEUTICS INC

Company Overview

Actuate Therapeutics Inc. is a clinical-stage Healthcare company in the Biotechnology industry focused on developing cancer therapies, led by elraglusib, a GSK-3β inhibitor with “pipeline in a molecule” potential across multiple difficult-to-treat cancers. Its most advanced program is in first-line metastatic pancreatic ductal adenocarcinoma, where Phase 2 data showed statistically significant overall survival benefit, and the company is also exploring pediatric oncology and other solid tumors. As a pre-revenue business, Actuate depends on third-party manufacturers, academic collaborators, and regulatory progress rather than commercial sales. Its small operating footprint and heavy reliance on trial outcomes make it highly event-driven, with value tied to clinical, regulatory, and financing milestones.

Executive Compensation Practices

Executive compensation at Actuate is likely shaped by the company’s clinical-stage, pre-commercial profile, where stock-based compensation is a major pay component and cash preservation matters. The filing summaries show stock compensation increasing both in R&D and especially in G&A, which suggests equity awards are being used to attract and retain talent while limiting cash burn. In the Biotechnology industry, pay packages often emphasize milestone-based incentives tied to trial execution, regulatory submissions, and capital-raising success rather than revenue growth. For Actuate, compensation drivers are likely to include enrollment progress, top-line clinical readouts, FDA interaction, and the ability to secure additional financing to fund operations beyond mid-2026.

Insider Trading Considerations

Insider trading patterns for Actuate should be viewed through the lens of a micro-cap, clinical-stage oncology company with binary catalysts and limited liquidity. Transactions may cluster around major clinical announcements, FDA correspondence, financing events, or patent and partnership developments, since insiders often have the clearest view of trial timing and regulatory risk. Because the company is pre-revenue and has disclosed substantial doubt about going concern, insider buying or selling may be especially informative to researchers and day traders, though it can also reflect personal liquidity needs or equity compensation exercises. In the Biotechnology industry, trading restrictions around material nonpublic data are especially important because clinical results, protocol amendments, and funding needs can move the stock sharply.